Literature DB >> 34279830

Sex Differences and COVID-19.

Natalie Thomas1,2, Caroline Gurvich3, Jayashri Kulkarni3.   

Abstract

Biological sex and psychosocial gender both play a role in many disease outcomes, and the novel coronavirus disease (COVID-19) is no different. Clinical observations in COVID-19 patient data delineate clear disparities between males and females, indicating males are at a higher risk for poorer disease outcomes. Although we are yet to understand the sex and gender-based disparities specific to COVID-19, there is evidence for sex-based differences in the endocrine, immune and renin-angiotensin system, all systems implicated in COVID-19 outcomes. Such disparities are largely thought to be driven by sex chromosomes and modulating sex hormones, which are known to vary between sex, and across the reproductive lifespan. Understanding and exploiting these driving factors are critical to understanding the pathobiology of SARS-CoV-2 virus and may lead to the development of novel therapies and increase the efficacy of preventative vaccine strategies currently under development. This chapter focuses on the endocrine, immune and renin-angiotensin system and genetic sex-based differences that could account for the meaningful differences observed in the outcomes of the SARS-CoV-2 infection.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  ACE inhibitors; COVID-19; Immune system; Pregnancy; Renin–angiotensin system; Sex differences; Sex hormones

Mesh:

Substances:

Year:  2021        PMID: 34279830     DOI: 10.1007/978-3-030-71697-4_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  63 in total

1.  COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

Authors:  Ankit B Patel; Ashish Verma
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

2.  COVID-19 pandemic, coronaviruses, and diabetes mellitus.

Authors:  Ranganath Muniyappa; Sriram Gubbi
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-03-31       Impact factor: 4.310

Review 3.  Laboratory Findings of COVID-19 Infection are Conflicting in Different Age Groups and Pregnant Women: A Literature Review.

Authors:  Sina Vakili; Amir Savardashtaki; Sheida Jamalnia; Reza Tabrizi; Mohammad Hadi Nematollahi; Morteza Jafarinia; Hamed Akbari
Journal:  Arch Med Res       Date:  2020-06-11       Impact factor: 2.235

4.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.

Authors:  Haibo Zhang; Josef M Penninger; Yimin Li; Nanshan Zhong; Arthur S Slutsky
Journal:  Intensive Care Med       Date:  2020-03-03       Impact factor: 17.440

Review 5.  COVID-19 pandemic-a focused review for clinicians.

Authors:  M Cevik; C G G Bamford; A Ho
Journal:  Clin Microbiol Infect       Date:  2020-04-25       Impact factor: 8.067

Review 6.  Endocrine and metabolic aspects of the COVID-19 pandemic.

Authors:  Mónica Marazuela; Andrea Giustina; Manuel Puig-Domingo
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

7.  Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.

Authors:  Muthiah Vaduganathan; Orly Vardeny; Thomas Michel; John J V McMurray; Marc A Pfeffer; Scott D Solomon
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245

8.  Real estimates of mortality following COVID-19 infection.

Authors:  David Baud; Xiaolong Qi; Karin Nielsen-Saines; Didier Musso; Léo Pomar; Guillaume Favre
Journal:  Lancet Infect Dis       Date:  2020-03-12       Impact factor: 25.071

9.  COVID-19: the gendered impacts of the outbreak.

Authors:  Clare Wenham; Julia Smith; Rosemary Morgan
Journal:  Lancet       Date:  2020-03-06       Impact factor: 79.321

10.  Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.

Authors:  Xin Zou; Ke Chen; Jiawei Zou; Peiyi Han; Jie Hao; Zeguang Han
Journal:  Front Med       Date:  2020-03-12       Impact factor: 4.592

View more
  2 in total

1.  Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer.

Authors:  Yuling Han; Jiaxin Yang; Danshuang He; Yang Feng; Xiaoman Liu; Yu Min; Shenghao Fan; Guobing Yin; Daixing Hu
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

2.  Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19.

Authors:  Anna E Spiering; Teun J de Vries
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.